SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
0003319707306144v1
59/5/542    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Isma, N.
Right arrow Articles by Gottsäter, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isma, N.
Right arrow Articles by Gottsäter, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia

Nazim Isma, MD*, Jamal Barani, PhD, Ingrid Mattiason, MD, PhD, Bengt Lindblad, MD, PhD, and Anders Gottsäter, MD, PhD

Malmo University Hospital

* To whom correspondence should be addressed. E-mail: nazim.isma{at}skane.se.


  Abstract
To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-{alpha}, interleukin-6 (IL6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF2{alpha}, and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering therapy on 3year survival was significant with inflammatory markers entered into the model one by one but disappeared when all inflammatory markers were entered into the model together. In conclusion, hs-CRP and IL-6 levels were lower and 3-year survival was higher in CLI patients on lipid-lowering therapy.

First published on April 2, 2008, doi:10.1177/0003319707306144

Angiology 2008;59:542.

A more recent version of this article appeared on October 1, 2008

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
K. I. Paraskevas, C. Psathas, T. Dragios, D. G. Chatzis, D. P. Mikhailidis, and Z. S. Kyriakides
The Impact of Novel Treatment Modalities on the Therapeutic Approach of Cardiovascular Diseases
Angiology, February 1, 2009; 60(1): 5 - 7.
[PDF]

Home page
 ANGIOLOGYHome page
K. I. Paraskevas, N. Bessias, T. T. Papas, V. Andrikopoulos, and D. P. Mikhailidis
Is High-sensitivity C-reactive Protein Associated With Subclinical Peripheral Atherosclerosis?
Angiology, February 1, 2009; 60(1): 8 - 11.
[PDF]


Advertisement